Acute corrosive esophagitis is an inflammation caused by severe damage to the esophagus caused by swallowing chemical corrosives such as strong acids and bases. The treatment of this disease includes the management of the acute inflammatory stage (early stage) and the scar stenosis stage (late stage). Early treatment: 1. General treatment: Those who are seriously ill should rest in bed and closely observe the changes in their condition. If there is no esophageal or gastric perforation, the condition is relatively mild, you can gargle with warm water; if you can still swallow, you can give protein water or vegetable oil to make it protect the esophageal and gastric mucosa. 2.Sedation and analgesia. 3.Esophageal rest: Reduce eating or suspend eating in the early stage to facilitate rest and recovery of the esophagus. At this time, attention should be paid to the balance of water and electrolytes, as well as nutrient supplementation. 4.Prevention of infection: Select appropriate antibacterial drugs according to the needs of the condition. 5.Mucosal protective agents: For alkaline corrosive esophagitis caused by sodium hydroxide, early use of recombinant bovine basic fibroblast growth factor can effectively prevent esophageal stricture, heparin can also effectively reduce inflammation and granulation tissue formation, mitomycin C can effectively prevent collagen deposition, and these can help prevent esophageal stricture. Some studies have suggested that glucocorticoids can reduce inflammation and reduce scar tissue proliferation. 6.Other treatment: In case of severe vomiting, vomiting blood, difficulty in whistling, shock or esophageal perforation, appropriate emergency treatment should be given. 7. Early surgical treatment: Severe acute corrosive esophagitis may be fatal, and patients who survive often have varying degrees of complications. Early emergency surgery may play an important role in preventing necrosis and perforation of the esophagus and stomach. This is especially true for those with strong alkaline corrosive esophagitis. Therefore, early surgical treatment should be considered in patients with severe esophageal corrosiveness when deep burns of the esophagus are expected and recovery is not easy in the short term. Late treatment: Late treatment mainly deals with advanced scarring esophageal strictures. Early esophageal obstruction in this disease is often due to acute inflammation and esophageal spasm, and if dysphagia reappears after 2-3 weeks, esophageal X-ray or gastroscopy should be performed to determine whether there are signs of early strictures. It is generally accepted that esophageal dilatation should be performed as early as possible for those who may have esophageal stricture without extraesophageal complications, but it should not be performed too early to avoid aggravating local and systemic reactions. Most experts and scholars recommend that esophageal dilatation treatment be performed at 2-3 weeks. In those with grade III injury, the timing of esophageal dilatation treatment varies from person to person, and early dilatation is more effective and can be performed cautiously after discontinuation of hormones (6-8 weeks). Stent placement therapy is generally not recommended because of the problem of restenosis. Those with ineffective dilatation therapy or severe, multisegmental stenosis should undergo surgical treatment as early as possible. Prognosis: Patients with mild cases of this disease may be free of complications and have a good prognosis. Severely ill patients are prone to acute complications such as esophageal perforation, hemorrhage, tracheoesophageal fistula, and have a high morbidity and mortality rate. More than 70% of patients with esophageal burns of degree II or higher will develop strictures. These patients with esophageal strictures have a significantly increased risk of esophageal cancer, which has a better prognosis than general esophageal cancer and may be related to its occurrence on scar tissue or easy detection, so close follow-up is needed.